Alpha adrenergic antagonist

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is developing and not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.

In pharmacology, alpha adrenergic blockers are "drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma."[1] They are also used for benign prostatic hyperplasia.

Naftopidil is more selective for the alpha-1a adrenergic receptor and has been used to treat benign prostatic hyperplasia.[2] Vascular drug toxicity may be less with tamsulosin due to more selectivity to α1-A and α1-D adrenergic receptors according to a meta-analysis supported by Boehringer Ingelheim Pharmaceuticals, the maker of tamsulosin.[3]

Costs

According to drugstore.com:

References

  1. Anonymous (2015), Alpha adrenergic antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Garimella PS, Fink HA, Macdonald R, Wilt TJ (2009). "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.". Cochrane Database Syst Rev (4): CD007360. DOI:10.1002/14651858.CD007360.pub2. PMID 19821408. Research Blogging.
  3. Nickel JC, Sander S, Moon TD (2008). "A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.". Int J Clin Pract 62 (10): 1547-59. DOI:10.1111/j.1742-1241.2008.01880.x. PMID 18822025. PMC PMC2658011. Research Blogging.